NEWS

Blog » Injections for Knee Osteoarthritis – 'Subtle but Significant' Impact of Revisions in Clinical Practice Guidelines

Injections for Knee Osteoarthritis – 'Subtle but Significant' Impact of Revisions in Clinical Practice Guidelines

Created May 17 2018, 03:38 PM by Wolters Kluwer Health
  • Journal of Bone and Joint Surgery

May 17, 2018 – Recent updates in evidence-based recommendations have led to changes in the use of steroid and hyaluronic acid injection for patients with osteoarthritis of the knee, reports a study in the May 16, 2018 issue of The Journal of Bone & Joint Surgery. The journal is published in partnership in the Lippincott portfolio by Wolters Kluwer.

Although guideline revisions based on new evidence have stopped or reversed trends towards increased use of injections for knee osteoarthritis, these treatments remain commonly used, according to the new research by Nicholas A. Bedard, MD, of University of Iowa Hospitals and Clinics, Iowa City, and colleagues.

Guideline Changes Reflect Questions on Injections for Knee Arthritis

The researchers evaluated the impact of updated guidelines for nonsurgical treatment of knee osteoarthritis, issued by the American Academy of Orthopaedic Surgeons (AAOS) in 2008 and 2013. The study focused on two common treatments to reduce knee pain: corticosteroid (steroid) injection, intended to reduce inflammation; and hyaluronic acid, intended to supplement the natural fluids within the knee joint.

Dr. Bedard and colleagues analyzed an insurance database of more than 1 million patients with knee osteoarthritis treated between 2007 and 2015. Overall, about 38 percent of patients received at least one steroid injection and 13 percent had at least one hyaluronic acid injection.

Before the first clinical practice guideline, the rate of steroid injections was rising steadily. In the 2008 guideline, the AAOS suggested that steroid injection could be given for short-term pain relief of knee. After this "Grade B" recommendation – reflecting some limitations of the evidence – the rate of increase in steroid injection slowed significantly.

By 2013, there was new conflicting evidence on effectiveness of steroid injection. In response, the AAOS stated that it could not make any recommendation for or against the use of steroid injection. After this revision, the trend in steroid injection leveled off. Use of steroid injection continued to increase in patients under age 50 – perhaps reflecting attempts to avoid total knee replacement surgery in this younger age group.

Recommendations for injection of hyaluronic acid were also revised during the study period. In 2008, the AAOS stated that there was no evidence on which to base a recommendation on hyaluronic acid injection, either for or against. This recommendation slowed a previous trend toward increased use of hyaluronic acid.

By 2013, there was new evidence showing no benefit of hyaluronic acid compared to inactive placebo, prompting a strong recommendation against the use of this treatment. After this revision, the rate of hyaluronic acid injection declined significantly.

There was a significant decrease in hyaluronic acid injections performed by orthopaedic surgeons and pain specialists – but not by primary care physicians (such as general internal medicine doctors) or non-surgeon musculoskeletal specialists (such as rheumatologists or sports medicine physicians). Overall, orthopaedic surgeons performed two-thirds of hyaluronic acid injections. Trends in steroid injection did not differ by specialty.

Evidence-based guidelines play an important role in ongoing evaluation of medical treatments. The new findings suggest that guideline updates for knee osteoarthritis have had a "subtle but significant" impact on clinical practice. Rates of steroid injection leveled off after the AAOS concluded that no recommendation could be made, while the rate of hyaluronic acid injection decreased in response to a recommendation against this procedure.

Some of the same studies that questioned the effectiveness of these treatments also reported that they account for a large proportion of treatment costs for knee osteoarthritis. Injections given shortly before total knee replacement surgery may even increase the risk of infection. Dr. Bedard comments, "We hope that this project helps to shed light on the important clinical practice guidelines created by AAOS and further encourages providers to follow these recommendations, share them with their patients, and utilize them as a guide to improve the value of care provided to patients with knee osteoarthritis."

Click here to read “Impact of Clinical Practice Guidelines on Use of Intra-Articular Hyaluronic Acid and Corticosteroid Injections for Knee Osteoarthritis.”

DOI: 10.2106/JBJS.17.01045

###

About The Journal of Bone & Joint Surgery

The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information, software solutions, and services for the health, tax & accounting, finance, risk & compliance, and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer, headquartered in the Netherlands, reported 2017 annual revenues of €4.4 billion. The company serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide.

Wolters Kluwer Health is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.

Media Contacts

Connie Hughes

Director, Corporate Communications, Health Learning, Research & Practice

+1 646-674-6348​

Email

Ellen Robinson 

Public Relations & Social Media Specialist, Health Learning, Research & Practice

+1 704-962-5912

Email

Loading